Foghorn Therapeutics (FHTX) Cash & Equivalents (2019 - 2026)

Foghorn Therapeutics' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $87.7 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 43.65% year-over-year to $87.7 million in Q1 2026; TTM through Mar 2026 was $87.7 million, a 43.65% increase from a year earlier, with the FY2025 full-year figure at $80.9 million, up 45.84% from the prior year.
• Cash & Equivalents improved to $87.7 million in Q1 2026 per FHTX's latest filing, from $80.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $213.6 million in Q1 2022 and bottomed at $50.6 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $72.6 million (2025), against an average of $82.1 million.
• Across the five-year window, Cash & Equivalents surged 221.52% in 2022 and slumped 76.3% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $52.2 million in 2022, then surged by 53.86% to $80.3 million in 2023, then slumped by 30.97% to $55.5 million in 2024, then surged by 45.84% to $80.9 million in 2025, then increased by 8.39% to $87.7 million in 2026.
• Per Business Quant, the three latest FHTX Cash & Equivalents figures stand at $87.7 million (Q1 2026), $80.9 million (Q4 2025), and $89.3 million (Q3 2025).